Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old and expected to live for more than 12 weeks.
- People who have been diagnosed with a specific type of brain/central nervous system lymphoma called DLBCL-type (confirmed by a tissue biopsy).
- People in Group 1: Those whose CNS lymphoma has come back after previous treatment, with visible disease on a brain scan.
- People in Group 2: Those who have been newly diagnosed with primary CNS lymphoma and are planned to receive a standard combination of chemotherapy drugs (high-dose methotrexate, temozolomide, and rituximab).
- People who have a brain scan taken within two weeks of joining that shows an active lymphoma lesion of at least one centimetre in size, using a special contrast dye (gadolinium).
- People whose lymphoma has also spread to the fluid around the brain/spine or the eyes — this is still permitted.
- People whose kidneys are working well enough (confirmed by a blood test done within 21 days before the imaging scan).
- People who are eligible, in their doctor's opinion, to receive high-dose methotrexate chemotherapy.
- People of any gender or racial/ethnic background — the trial actively recruits minorities, and no one is excluded based on race.
- People who sign the required consent forms agreeing to take part and to allow their health information to be used for the study.
Who may not be able to join:
- People who have significant medical conditions that, in the opinion of the treating doctor, cannot be well managed or that could interfere with the imaging or treatment results.
- People with moderate or severe heart failure (classified as New York Heart Association Grade II or higher).
- People who have had another cancer in the past, unless it was a minor skin cancer or a cervical pre-cancer, or unless they have been in full remission and off all cancer treatment for more than three years.
- People who are pregnant or breastfeeding. A negative pregnancy test within 14 days of the imaging scan is required for people who could become pregnant. Effective contraception must be used by participants who could father or carry a child.
- People who are not able to follow the study procedures and required follow-up visits.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: James Rubenstein, MD, PhD, University of California, San Francisco
Phone: (415) 514-4418
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with treatment-emergent Adverse Events; Number of participants with abnormal changes in vital signs; Number of participants with abnormal changes in injection site; Percent of eligible patients that complete the study; Pyruvate-to lactate conversion (kPL); Number of participants with response; Signal Amplitudes; Time Dynamics
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.